Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Serial imaging after pulmonary embolism and correlation with functional limitation at 12 months: Results of the ELOPE Study.

Ma KA, Kahn SR, Akaberi A, Dennie C, Rush C, Granton JT, Anderson D, Wells PS, Rodger MA, Solymoss S, Kovacs MJ, Rudski L, Shimony A, Hernandez P, Aaron SD, Pena E, Abikhzer G, Hirsch AM; ELOPE Study group.

Res Pract Thromb Haemost. 2018 Jun 17;2(4):670-677. doi: 10.1002/rth2.12123. eCollection 2018 Oct.

2.

"HERDOO2" clinical decision rule to guide duration of anticoagulation in women with unprovoked venous thromboembolism. Can I use any d-Dimer?

Rodger MA, Le Gal G, Langlois NJ, Gin B, Mallick R, Giulivi A, Freedman M, Kovacs MJ; REVERSE II investigators.

Thromb Res. 2018 Sep;169:82-86. doi: 10.1016/j.thromres.2018.07.020. Epub 2018 Jul 17.

3.

Prevention of venous thromboembolism in pregnant patients with a history of venous thromboembolic disease: A retrospective cohort study.

Lazo-Langner A, Al-Ani F, Weisz S, Rozanski C, Louzada M, Kovacs J, Kovacs MJ.

Thromb Res. 2018 Jul;167:20-25. doi: 10.1016/j.thromres.2018.05.005. Epub 2018 May 5.

PMID:
29772489
4.

Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.

Anderson DR, Dunbar M, Murnaghan J, Kahn SR, Gross P, Forsythe M, Pelet S, Fisher W, Belzile E, Dolan S, Crowther M, Bohm E, MacDonald SJ, Gofton W, Kim P, Zukor D, Pleasance S, Andreou P, Doucette S, Theriault C, Abianui A, Carrier M, Kovacs MJ, Rodger MA, Coyle D, Wells PS, Vendittoli PA.

N Engl J Med. 2018 Feb 22;378(8):699-707. doi: 10.1056/NEJMoa1712746.

5.

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.

Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai VTE Cancer Investigators.

N Engl J Med. 2018 Feb 15;378(7):615-624. doi: 10.1056/NEJMoa1711948. Epub 2017 Dec 12.

6.

Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study.

Wan T, Rodger M, Zeng W, Robin P, Righini M, Kovacs MJ, Tan M, Carrier M, Kahn SR, Wells PS, Anderson DR, Chagnon I, Solymoss S, Crowther M, White RH, Vickars L, Bazarjani S, Le Gal G.

Thromb Res. 2018 Feb;162:104-109. doi: 10.1016/j.thromres.2017.11.020. Epub 2017 Dec 8.

PMID:
29224973
7.

Association between remote major venous thromboembolism risk factors and the risk of recurrence after a first unprovoked episode.

Farren-Dai L, Carrier M, Kovacs J, Rodger M, Kovacs MJ, Le Gal G; REVERSE investigators.

J Thromb Haemost. 2017 Oct;15(10):1977-1980. doi: 10.1111/jth.13796. Epub 2017 Sep 6.

PMID:
28795538
8.

A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2).

Davies GA, Lazo-Langner A, Gandara E, Rodger M, Tagalakis V, Louzada M, Corpuz R, Kovacs MJ.

Thromb Res. 2018 Feb;162:88-92. doi: 10.1016/j.thromres.2017.04.003. Epub 2017 Apr 6.

PMID:
28416213
9.

Quality of Life, Dyspnea, and Functional Exercise Capacity Following a First Episode of Pulmonary Embolism: Results of the ELOPE Cohort Study.

Kahn SR, Akaberi A, Granton JT, Anderson DR, Wells PS, Rodger MA, Solymoss S, Kovacs MJ, Rudski L, Shimony A, Dennie C, Rush C, Hernandez P, Aaron SD, Hirsch AM.

Am J Med. 2017 Aug;130(8):990.e9-990.e21. doi: 10.1016/j.amjmed.2017.03.033. Epub 2017 Apr 8.

PMID:
28400247
10.

N-terminal of prohormone brain natriuretic peptide predicts functional limitation one year following pulmonary embolism: Results from the ELOPE study.

Ma K, Kahn SR, Hirsch AM, Akaberi A, Anderson DR, Wells PS, Rodger M, Solymoss S, Kovacs MJ, Rudski L, Shimony A, Dennie C, Rush C, Hernandez P, Aaron SD, Granton JT.

Thromb Res. 2017 May;153:47-49. doi: 10.1016/j.thromres.2017.03.005. Epub 2017 Mar 8. No abstract available.

PMID:
28319825
11.

Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study.

Rodger MA, Le Gal G, Anderson DR, Schmidt J, Pernod G, Kahn SR, Righini M, Mismetti P, Kearon C, Meyer G, Elias A, Ramsay T, Ortel TL, Huisman MV, Kovacs MJ; REVERSE II Study Investigators.

BMJ. 2017 Mar 17;356:j1065. doi: 10.1136/bmj.j1065.

12.

Functional and Exercise Limitations After a First Episode of Pulmonary Embolism: Results of the ELOPE Prospective Cohort Study.

Kahn SR, Hirsch AM, Akaberi A, Hernandez P, Anderson DR, Wells PS, Rodger MA, Solymoss S, Kovacs MJ, Rudski L, Shimony A, Dennie C, Rush C, Geerts WH, Aaron SD, Granton JT.

Chest. 2017 May;151(5):1058-1068. doi: 10.1016/j.chest.2016.11.030. Epub 2016 Dec 6.

PMID:
27932051
13.

Impact of thrombophilia screening on venous thromboembolism management practices.

Garcia-Horton A, Kovacs MJ, Abdulrehman J, Taylor JE, Sharma S, Lazo-Langner A.

Thromb Res. 2017 Jan;149:76-80. doi: 10.1016/j.thromres.2016.11.023. Epub 2016 Dec 1.

PMID:
27931012
14.

The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. A randomised trial.

Boonyawat K, Wang L, Lazo-Langner A, Kovacs MJ, Yeo E, Schnurr T, Schulman S, Crowther MA.

Thromb Haemost. 2016 Aug 30;116(3):480-5. doi: 10.1160/TH16-04-0320. Epub 2016 Jun 23.

PMID:
27346552
15.

A multicenter prospective study of risk factors and treatment of unusual site thrombosis.

Ma K, Wells P, Guzman C, Anderson D, Blostein M, Hirsch A, Lazo-Langner A, Kovacs MJ, Rodger M, Tagalakis V, Kahn SR.

Thromb Res. 2016 Aug;144:100-5. doi: 10.1016/j.thromres.2016.04.014. Epub 2016 Apr 26.

PMID:
27318246
16.

Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: A multi-national cohort.

Rodger MA, Scarvelis D, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, Gandara E, Solymoss S, Sabri E, Kovacs J, Kovacs MJ.

Thromb Res. 2016 Jul;143:152-8. doi: 10.1016/j.thromres.2016.03.028. Epub 2016 Mar 29.

17.

Screening of patients with idiopathic venous thromboembolism for paroxysmal nocturnal hemoglobinuria clones.

Lazo-Langner A, Kovacs MJ, Hedley B, Al-Ani F, Keeney M, Louzada ML, Chin-Yee I.

Thromb Res. 2015 Jun;135(6):1107-9. doi: 10.1016/j.thromres.2015.04.006. Epub 2015 Apr 11.

PMID:
25890452
18.

Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.

Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman MV, Bergqvist D, Turpie AG, Ortel TL, Spyropoulos AC, Pabinger I, Kakkar AK.

J Thromb Haemost. 2015 Jun;13(6):1028-35. doi: 10.1111/jth.12923. Epub 2015 May 10.

19.

Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study.

Kang M, Alahmadi M, Sawh S, Kovacs MJ, Lazo-Langner A.

Blood. 2015 Feb 5;125(6):924-9. doi: 10.1182/blood-2014-09-599498. Epub 2014 Dec 16.

20.

Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post-thrombotic syndrome.

Rabinovich A, Cohen JM, Cushman M, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, Tagalakis V, Lazo-Langner A, Solymoss S, Miron MJ, Yeo E, Smith R, Schulman S, Kassis J, Kearon C, Chagnon I, Wong T, Demers C, Hanmiah R, Kaatz S, Selby R, Rathbun S, Desmarais S, Opatrny L, Ortel TL, Ginsberg JS, Kahn SR.

J Thromb Haemost. 2015 Mar;13(3):398-408. doi: 10.1111/jth.12814. Epub 2015 Feb 10.

21.

Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10.

Kovacs MJ, Davies GA, Chapman JA, Bahlis N, Voralia M, Roy J, Kouroukis CT, Chen C, Belch A, Reece D, Zhu L, Meyer RM, Shepherd L, Stewart KA.

Br J Haematol. 2015 Feb;168(4):511-7. doi: 10.1111/bjh.13176. Epub 2014 Oct 10.

PMID:
25302852
22.

Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.

Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, Davidson BL, Beyer-Westendorf J, Pap ÁF, Berkowitz SD, Cohen AT, Kovacs MJ, Wells PS, Prandoni P.

Lancet Haematol. 2014 Oct;1(1):e37-46. doi: 10.1016/S2352-3026(14)70018-3. Epub 2014 Sep 28.

PMID:
27030066
23.

Graduated compression stockings to treat acute leg pain associated with proximal DVT. A randomised controlled trial.

Kahn SR, Shapiro S, Ducruet T, Wells PS, Rodger MA, Kovacs MJ, Anderson D, Tagalakis V, Morrison DR, Solymoss S, Miron MJ, Yeo E, Smith R, Schulman S, Kassis J, Kearon C, Chagnon I, Wong T, Demers C, Hanmiah R, Kaatz S, Selby R, Rathbun S, Desmarais S, Opatrny L, Ortel TL, Galanaud JP, Ginsberg JS.

Thromb Haemost. 2014 Dec;112(6):1137-41. doi: 10.1160/TH14-05-0430. Epub 2014 Aug 28.

PMID:
25183442
24.

Treatment priorities in oncology: do we want to live longer or better?

Marta GN, Del Nero LG, Marta GN, Mangabeira A, Critchi G, Kovács MJ, Silva JL, Saad ED.

Clinics (Sao Paulo). 2014 Aug;69(8):509-14.

25.

Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial.

Rodger MA, Hague WM, Kingdom J, Kahn SR, Karovitch A, Sermer M, Clement AM, Coat S, Chan WS, Said J, Rey E, Robinson S, Khurana R, Demers C, Kovacs MJ, Solymoss S, Hinshaw K, Dwyer J, Smith G, McDonald S, Newstead-Angel J, McLeod A, Khandelwal M, Silver RM, Le Gal G, Greer IA, Keely E, Rosene-Montella K, Walker M, Wells PS; TIPPS Investigators.

Lancet. 2014 Nov 8;384(9955):1673-83. doi: 10.1016/S0140-6736(14)60793-5. Epub 2014 Jul 24.

PMID:
25066248
26.

Initial management of noncirrhotic splanchnic vein thrombosis: when is anticoagulation enough?

Ravichandran P, Croome KP, Kovacs MJ, Lazo-Langner A, Hernandez-Alejandro R.

Can J Gastroenterol Hepatol. 2014 Apr;28(4):207-11.

27.

Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia.

Yee KW, Storring JM, Buckstein R, Wells RA, Xenocostas A, Kovacs MJ, Howson-Jan K, Wang ES, Battista K, Wang L, Oza AM, Ivy SP, Schuh AC.

Leuk Lymphoma. 2014 Nov;55(11):2669-71. doi: 10.3109/10428194.2014.900763. Epub 2014 Apr 22. No abstract available.

PMID:
24611649
28.

Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial.

Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, Tagalakis V, Houweling AH, Ducruet T, Holcroft C, Johri M, Solymoss S, Miron MJ, Yeo E, Smith R, Schulman S, Kassis J, Kearon C, Chagnon I, Wong T, Demers C, Hanmiah R, Kaatz S, Selby R, Rathbun S, Desmarais S, Opatrny L, Ortel TL, Ginsberg JS; SOX trial investigators.

Lancet. 2014 Mar 8;383(9920):880-8. doi: 10.1016/S0140-6736(13)61902-9. Epub 2013 Dec 6.

PMID:
24315521
29.

Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis.

Donadini MP, Ageno W, Antonucci E, Cosmi B, Kovacs MJ, Le Gal G, Ockelford P, Poli D, Prandoni P, Rodger M, Saccullo G, Siragusa S, Young L, Bonzini M, Caprioli M, Dentali F, Iorio A, Douketis JD.

Thromb Haemost. 2014 Jan;111(1):172-9. doi: 10.1160/TH13-04-0336. Epub 2013 Oct 24.

PMID:
24154729
30.

Device surgery without interruption of anticoagulation.

Skeith L, Kovacs MJ, Douketis JD.

N Engl J Med. 2013 Oct 17;369(16):1570-1. doi: 10.1056/NEJMc1310241. No abstract available.

PMID:
24131190
31.

Non-OO blood type influences the risk of recurrent venous thromboembolism. A cohort study.

Gándara E, Kovacs MJ, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, Solymoss S, Crowther M, Carrier M, Langlois N, Kovacs J, Little Ma J, Carson N, Ramsay T, Rodger MA.

Thromb Haemost. 2013 Dec;110(6):1172-9. doi: 10.1160/TH13-06-0488. Epub 2013 Sep 26.

PMID:
24067945
32.

The equipoise of perioperative anticoagulation management: a Canadian cross-sectional survey.

Skeith L, Lazo-Langner A, Kovacs MJ.

J Thromb Thrombolysis. 2014 May;37(4):411-3. doi: 10.1007/s11239-013-0960-6. No abstract available.

PMID:
23868474
33.

A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.

Stewart AK, Trudel S, Bahlis NJ, White D, Sabry W, Belch A, Reiman T, Roy J, Shustik C, Kovacs MJ, Rubinger M, Cantin G, Song K, Tompkins KA, Marcellus DC, Lacy MQ, Sussman J, Reece D, Brundage M, Harnett EL, Shepherd L, Chapman JA, Meyer RM.

Blood. 2013 Feb 28;121(9):1517-23. doi: 10.1182/blood-2012-09-451872. Epub 2013 Jan 7.

34.

Predictors of post-thrombotic syndrome in a population with a first deep vein thrombosis and no primary venous insufficiency.

Galanaud JP, Holcroft CA, Rodger MA, Kovacs MJ, Betancourt MT, Wells PS, Anderson DR, Chagnon I, Le Gal G, Solymoss S, Crowther MA, Perrier A, White RH, Vickars LM, Ramsay T, Kahn SR.

J Thromb Haemost. 2013 Mar;11(3):474-80. doi: 10.1111/jth.12106.

35.

Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial.

White DJ, Bahlis NJ, Marcellus DC, Belch A, Stewart AK, Chen C, Kovacs MJ, Macdonald DA, Reece DE, Reiman T, Harnett E, Meyer RM, Chapman JA, Couban S.

Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):19-24. doi: 10.1016/j.clml.2012.08.009. Epub 2012 Nov 7.

PMID:
23141150
36.

Family history of venous thromboembolism (VTE) as a predictor for recurrent VTE in unprovoked VTE patients.

Gauthier K, Kovacs MJ, Wells PS, Le Gal G, Rodger M; REVERSE investigators.

J Thromb Haemost. 2013 Jan;11(1):200-3. doi: 10.1111/jth.12048. No abstract available.

37.

Should vitamin K antagonist therapy be started simultaneously with parenteral anticoagulation: a meta-analysis?

Qayyum F, Holbrook A, Lam J, Kovacs MJ, Schulman S.

Blood Coagul Fibrinolysis. 2012 Dec;23(8):705-13. doi: 10.1097/MBC.0b013e328357431f.

PMID:
23080362
38.

Conservative perioperative anticoagulation management in patients with chronic venous thromboembolic disease: a cohort study.

Skeith L, Taylor J, Lazo-Langner A, Kovacs MJ.

J Thromb Haemost. 2012 Nov;10(11):2298-304. doi: 10.1111/j.1538-7836.2012.04907.x.

39.

Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study.

Chitsike RS, Rodger MA, Kovacs MJ, Betancourt MT, Wells PS, Anderson DR, Chagnon I, LE Gal G, Solymoss S, Crowther MA, Perrier A, White RH, Vickars LM, Ramsay T, Kahn SR.

J Thromb Haemost. 2012 Oct;10(10):2039-44. doi: 10.1111/j.1538-7836.2012.04872.x.

40.

Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism.

Louzada ML, Carrier M, Lazo-Langner A, Dao V, Kovacs MJ, Ramsay TO, Rodger MA, Zhang J, Lee AY, Meyer G, Wells PS.

Circulation. 2012 Jul 24;126(4):448-54. doi: 10.1161/CIRCULATIONAHA.111.051920. Epub 2012 Jun 7.

PMID:
22679142
41.

Comparison of the Villalta post-thrombotic syndrome score in the ipsilateral vs. contralateral leg after a first unprovoked deep vein thrombosis.

Galanaud JP, Holcroft CA, Rodger MA, Kovacs MJ, Betancourt MT, Wells PS, Anderson DR, Chagnon I, Le Gal G, Solymoss S, Crowther MA, Perrier A, White RH, Vickars LM, Ramsay T, Kahn SR.

J Thromb Haemost. 2012 Jun;10(6):1036-42. doi: 10.1111/j.1538-7836.2012.04713.x.

42.

Bleeding risk assessment during oral anticoagulant therapy initiation.

Lazo-Langner A, Kovacs MJ, Louzada M.

Expert Rev Hematol. 2012 Apr;5(2):125-7. doi: 10.1586/ehm.12.10. No abstract available.

PMID:
22475279
43.

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH.

Chest. 2012 Feb;141(2 Suppl):e152S-e184S. doi: 10.1378/chest.11-2295. Review.

44.

Study of Octaplex dosing accuracy: an in vitro analysis.

Patriquin CJ, Chin-Yee IH, Kovacs MJ, Lazo-Langner A, Keeney M, Hsia CC.

Thromb Haemost. 2012 Feb;107(2):248-52. doi: 10.1160/TH11-09-0610. Epub 2011 Dec 21.

PMID:
22186847
45.

Baseline imaging after therapy for unprovoked venous thromboembolism: a randomized controlled comparison of baseline imaging for diagnosis of suspected recurrence.

Hamadah A, Alwasaidi T, LE Gal G, Carrier M, Wells PS, Scarvelis D, Gonsalves C, Forgie M, Kovacs MJ, Rodger MA.

J Thromb Haemost. 2011 Dec;9(12):2406-10. doi: 10.1111/j.1538-7836.2011.04533.x.

46.

Psychological impact of thrombophilia testing in asymptomatic family members.

Louzada ML, Taljaard M, Langlois NJ, Kahn SR, Rodger MA, Anderson DR, Kovacs MJ, Wells PS.

Thromb Res. 2011 Dec;128(6):530-5. doi: 10.1016/j.thromres.2011.05.024. Epub 2011 Jul 6.

PMID:
21737129
47.

More on: lupus anticoagulant testing during acute thrombotic events.

Kovacs MJ, Louzada M, Lazo-Langner A.

J Thromb Haemost. 2011 Aug;9(8):1682-3. doi: 10.1111/j.1538-7836.2011.04379.x. No abstract available.

48.
49.

Low prevalence of JAK2 V617F mutation in patients with first unprovoked venous thromboembolism.

Rodger MA, Kekre N, Le Gal G, Kahn SR, Wells PS, Anderson DA, Chagnon I, Solymoss S, Crowther M, Perrier A, White R, Vickars L, Ramsay T, Betancourt MT, Kovacs MJ.

Br J Haematol. 2011 Nov;155(4):511-3. doi: 10.1111/j.1365-2141.2011.08701.x. Epub 2011 Apr 26. No abstract available.

PMID:
21517823
50.

The management of a sub-segmental pulmonary embolism: a cross-sectional survey of Canadian thrombosis physicians.

Carrier M, Kimpton M, LE Gal G, Kahn SR, Kovacs MJ, Wells PS, Anderson DR, Rodger MA.

J Thromb Haemost. 2011 Jul;9(7):1412-5. doi: 10.1111/j.1538-7836.2011.04306.x. No abstract available.

Supplemental Content

Loading ...
Support Center